Cannabidiol is indicated for use as adjunctive therapy of seizures associated with Lennox-Gastaut Syndrome in conjunction with clobazam, for patients two years of age and older.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||05/02/2020|
|Rapid review completed||11/03/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cannabidiol compared with the current standard of care.|